07AA93F0-3339-4EEC-B50B-ADB70F657087

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 10 USDMF, 4 CEP/COS, 9 JDMF, 14 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

FINISHED DOSAGE FORMULATIONS

128 FDF Dossiers, 11 FDA Orange Book, 19 Europe, 2 Canada, 25 South Africa, 71 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FOR SOLUTION;INTRAVENOUS - 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL, INJECTABLE;INTRAVENOUS - 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL, INJECTABLE;INJECTION - 20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 5 SPI Pharma, 7 DKSH, 1 Pharm-RX Chemical, 5 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 5 Kirsch Pharma, 4 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 15 BASF, 2 Bioplus Life Sciences, 1 CD Formulation, 8 Corel Pharma Chem, 3 DFE Pharma, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 2 Ideal Cures, 3 Ingredion Pharma Solutions, 4 Kerry, 2 Keval Exports, 3 Lonza Capsugel, 2 Lubrizol Life Science Health, 9 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qualicaps, 23 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Fillers, Diluents & Binders, 30 Thickeners and Stabilizers, 24 Topical, 23 Coating Systems & Additives, 21 Solubilizers, 18 Parenteral, 17 Direct Compression, 17 Lubricants & Glidants, 17 Disintegrants & Superdisintegrants, 14 Controlled & Modified Release, 12 Film Formers & Plasticizers, 12 Granulation, 12 Taste Masking, 11 Co-Processed Excipients, 10 Emulsifying Agents, 8 Empty Capsules, 6 Chewable & Orodispersible Aids, 3 Rheology Modifiers, 3 API Stability Enhancers, 3 Surfactant & Foaming Agents, 2 Coloring Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 8 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 Regulatory FDF Prices, 3 Annual Reports

MARKET PLACE

40 APIs, 3 EXCIPIENTS

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 5 JP, 7 Others

ANALYTICAL

7 Analytical Methods

7 Analytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 21625 / DOSAGE - INJECTABLE;INTRAVENOUS - 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL

Inactive Ingredients

Ingredient Name	Hospira, Inc.
BUTYLATED HYDROXYANISOLE(REK4960K2U)
BUTYLATED HYDROXYTOLUENE(1P9D0Z171K)
CITRIC ACID MONOHYDRATE(2968PHW8QP)
GENTISIC ACID ETHANOLAMIDE(H4E039OIGX)
POLYSORBATE 20(7T1F30V5YH)
POLYSORBATE 80(6OZP39ZG8H)
PROPYLENE GLYCOL(6DC9Q167V3)
SODIUM CITRATE, UNSPECIFIED FORM(1Q73Q2JULR)
SODIUM HYDROXIDE(55X04QC32I)

Setid 5e8320a4 C46e 4edb 3a97 760d2251fb45 Applno 21625 Form Injectable Intravenous Dosage 200mg Vial 0 06mg Vial 0 005mg Vial 15mg Vial 0 005mg Vial 0 6mg Vial 40mg Vial 6mg Vial 3 6mg Vial 6mg Vial 1mg Vial 10mg Vial 0 15mg Vial - Drug Product Composition: 07AA93F0-3339-4EEC-B50B-ADB70F657087